hotspot -WSS

hotspot

author：hotspot 2025-09-30 16:26:36 - browse：36771

A medical device to treat below-the-knee chronic limb-threatening ischemia, Esprit BTK resorbable scaffold, is shown consisted of pieces of geometric shapes that lined up into a pipe on a blue background — health tech coverage from STAT — Cardiovascular doctors are optimistic about Abbott’s new below-knee stent that disappears into the blood vessel’s walls over the course of three years. Courtesy Abbott

An Abbott device that failed in heart disease patients is getting a new life in patients with severe vascular disease.

The device is a below-knee stent that widens clogged blood vessels, and then vanishes into the vessel’s walls over the course of three years. It also delivers a drug that prevents scar tissue from forming — a common risk factor with traditional metal stents that further narrow the vessel.

Abbott’s first dissolvable stent, for coronary artery disease, received Food and Drug Administration approval in 2016. But the company voluntarily pulled the product from the market just over a year later due to “low commercial uptake.” The device also received mixed results in clinical trials.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout LOUD podcast: Live from the 2023 STAT Summit

focus

WSS

Merck, Daiichi strike cancer drug pact worth up to $22 billion

Why Titanic fascinates society, still drawing tours to the wreckage

Results on Novartis prostate cancer therapy could expand its use

STAT Readout: Friday, Oct. 20 biotech updates

How corporate America is slashing DEI workers amid backlash to diversity programs

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

Wikipedia

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Ahead of NATO summit, Biden meets with King Charles for 1st time since coronation

After affirmative action ruling, medical educators look to 'holistic review'

Father who lunged at Larry Nassar comforted by deputy who pinned him down: 'I understand'

Trump demands the U.S. pay no more for drugs than other countries … again

The PBM ad wars are taking over Washington, D.C.

What does generative AI mean for health care? We asked experts

Merck, Daiichi strike cancer drug pact worth up to $22 billion

At least 13 dead in Texas as scorching temps continue

Sen. Bill Cassidy on how to lower drug prices

Wikipedia

Roche acquires Telavant from Roivant, adding experimental IBD treatment

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

STAT Summit: Ending the crisis of Black deaths in the U.S.

Cassava Sciences’ Alzheimer’s clinical trials should be halted

Roche acquires Telavant from Roivant, adding experimental IBD treatment

Submersible on Titanic tour reported missing off Newfoundland with 5 people aboard

focus

focus

focus

leisure time